Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x109/L

MLA

Lawrence B. Afrin, et al. “Preliminary Safety and Efficacy of Ruxolitinib in Patients (Pts) with Primary and Secondary Myelofibrosis (MF) with Platelet Counts (PC) of 50–100x109/L.” Journal of Clinical Oncology, vol. 30, May 2012, p. 6630. EBSCOhost, https://doi.org/10.1200/jco.2012.30.15_suppl.6630.

APA

Lawrence B. Afrin, Elliott F. Winton, Josef T. Prchal, Maria R. Baer, Roger M. Lyons, Katarzyna Jamieson, Hagop M. Kantarjian, Chris E. Holmes, Moshe Talpaz, Jimmie H. Harvey, Howard R. Terebelo, Susan Erickson-Viitanen, Michael A. Scola, Lance Leopold, Richard T. Silver, Solomon I. Hamburg, Gregory L. Ortega, Wei Peng, Srdan Verstovsek, & Peter O’Neill. (2012). Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of 50–100x109/L. Journal of Clinical Oncology, 30, 6630. https://doi.org/10.1200/jco.2012.30.15_suppl.6630

Chicago

Lawrence B. Afrin, Elliott F. Winton, Josef T. Prchal, Maria R. Baer, Roger M. Lyons, Katarzyna Jamieson, Hagop M. Kantarjian, et al. 2012. “Preliminary Safety and Efficacy of Ruxolitinib in Patients (Pts) with Primary and Secondary Myelofibrosis (MF) with Platelet Counts (PC) of 50–100x109/L.” Journal of Clinical Oncology 30 (May): 6630. doi:10.1200/jco.2012.30.15_suppl.6630.